Drugs giant GlaxoSmithKline has taken out full-page advertisements in 15 major US newspapers to defend its diabetes treatment, Avandia.
The ads, which appeared today in major regional US newspapers such as The New York Times, The Washington Post, The Wall Street Journal, the LA Times and the Dallas Morning News, take the form of a letter to Avandia patients signed by Dr Ronald Krall, GSK's chief medical officer.
The unusual move comes a day before a US congressional hearing on the Food and Drug Administration's evaluation of the safety of Avandia. The FDA will convene specialists at a meeting on July 30.
A New York Times spokeswoman said a full-page ad with color in the A-section of the paper typically costs about $110,000.
More plus excerpts from the ad.
No comments:
Post a Comment